Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Forever Jung: how early psychological theory is still releva...

Matthew Hunt explores early psychological theory and applies it to current medical practice. For numerous and frankly reassuring reasons, healthcare practice in the 21st century has distanced itself from the darker arts of...

Articles

Patient perspectives: Amy Tenderich

As our Patient perspective series continues, we speak with Amy Tenderich on her experience as a diabetes patient and advocate and her ideas on where devices for diabetes should be heading. Back in 2003 at the time of Amy’s diagnosis there was little in the way of online patient resources or online areas where patients …

Articles

Crikey, what a headache – pharmaceutical litigation, compens...

Mabel Tsui discusses the progress to date of the Merck Sharp Dohme (Australia) Pty Ltd v Peterson case in Australia to date and how it highlights the need for tort law reform in Australia when it comes to pharmaceutical product litigation. In October 2011, the Full Court of the Federal Court of Australia handed down their judgment in the case...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.